BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

...still under evaluation in BLAZE-2, a Phase III post-exposure prophylactic study, as well as two outpatient trials.Amgen’s...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...race, but it’s still too early to tell how adagrasib (MRTX849) will stack up against Amgen’s...
...sotorasib (AMG 510) from Amgen Inc. (NASDAQ:AMGN).At last month’s European Society of Medical Oncology Virtual Congress, Amgen...
...13 treated patients.While Mirati’s new data point to higher response rates than those seen by Amgen...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...of Discovery Angel Guzman-Perez, a veteran of Amgen Inc....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Kymera Therapeutics Inc. (NASDAQ:KYMR), Nurix Therapeutics Inc. (NASDAQ:NRIX), Amgen Inc....
...can harness or inhibit new E3 ligases. Amgen...
...AUTACs) are also within the scope of Amgen’s...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

...and has been a senior executive at Amgen Inc....
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...after achieving a complete response (CR). The patient was treated with steroids, Kineret anakinra from Amgen Inc....
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...103, mt103, MEDI-538) Recarbrio, Relebactam/imipenem/cilastatin FDC (MK-7655A) Agios Pharmaceuticals Inc. Gilead Sciences Inc. Orchard Therapeutics plc Alnylam Pharmaceuticals Inc. Aimmune Therapeutics Inc. Amgen Inc. Johnson...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...Oct. 8 when Cytokinetics Inc. (NASDAQ:CYTK) and partners Amgen Inc....
...I candidates AMG 594 from partners Cytokinetics and Amgen...
...factor A Stephen Hansen Omecamtiv mecarbil (AMG 423, ck-1827452) Cytokinetics Inc. Amgen Inc. AstraZeneca...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...Biotherapeutics Inc. President and CEO Scott Foraker told BioCentury.Foraker and founder and CSO Alexander Kamb are Amgen Inc....
...Investments, and Hartford HealthCare EndowmentCEO: Scott ForakerPatents: None issuedTARGETSMHC – Major histocompatibility complex Danielle Golovin A2 Biotherapeutics Inc. Amgen Inc. CD19...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...trial. Biotech stays optimistic on omecamtiv even as heart failure data sink shares, shave $10B off Amgen’s...
...hansen, associate editor Pivotal heart failure data 14 years in the making tripped up Cytokinetics and Amgen...
...that drove Bristol Myers’ $13.1 billion takeout of MyoKardia this week.Cytokinetics Inc. (NASDAQ:CYTK) and partners Amgen Inc....
Items per page:
1 - 10 of 6759
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

...still under evaluation in BLAZE-2, a Phase III post-exposure prophylactic study, as well as two outpatient trials.Amgen’s...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...race, but it’s still too early to tell how adagrasib (MRTX849) will stack up against Amgen’s...
...sotorasib (AMG 510) from Amgen Inc. (NASDAQ:AMGN).At last month’s European Society of Medical Oncology Virtual Congress, Amgen...
...13 treated patients.While Mirati’s new data point to higher response rates than those seen by Amgen...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...of Discovery Angel Guzman-Perez, a veteran of Amgen Inc....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Kymera Therapeutics Inc. (NASDAQ:KYMR), Nurix Therapeutics Inc. (NASDAQ:NRIX), Amgen Inc....
...can harness or inhibit new E3 ligases. Amgen...
...AUTACs) are also within the scope of Amgen’s...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

...and has been a senior executive at Amgen Inc....
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...after achieving a complete response (CR). The patient was treated with steroids, Kineret anakinra from Amgen Inc....
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...103, mt103, MEDI-538) Recarbrio, Relebactam/imipenem/cilastatin FDC (MK-7655A) Agios Pharmaceuticals Inc. Gilead Sciences Inc. Orchard Therapeutics plc Alnylam Pharmaceuticals Inc. Aimmune Therapeutics Inc. Amgen Inc. Johnson...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...Oct. 8 when Cytokinetics Inc. (NASDAQ:CYTK) and partners Amgen Inc....
...I candidates AMG 594 from partners Cytokinetics and Amgen...
...factor A Stephen Hansen Omecamtiv mecarbil (AMG 423, ck-1827452) Cytokinetics Inc. Amgen Inc. AstraZeneca...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...Biotherapeutics Inc. President and CEO Scott Foraker told BioCentury.Foraker and founder and CSO Alexander Kamb are Amgen Inc....
...Investments, and Hartford HealthCare EndowmentCEO: Scott ForakerPatents: None issuedTARGETSMHC – Major histocompatibility complex Danielle Golovin A2 Biotherapeutics Inc. Amgen Inc. CD19...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...trial. Biotech stays optimistic on omecamtiv even as heart failure data sink shares, shave $10B off Amgen’s...
...hansen, associate editor Pivotal heart failure data 14 years in the making tripped up Cytokinetics and Amgen...
...that drove Bristol Myers’ $13.1 billion takeout of MyoKardia this week.Cytokinetics Inc. (NASDAQ:CYTK) and partners Amgen Inc....
Items per page:
1 - 10 of 6759